Welcome to Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer. In addition, the Company owns the Photodynamic Therapy technology for oncology and dermatology applications, licensed to BioCeltran Co., Ltd. (Bioceltran), a Korea based company. Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes. Quest also markets consumer health products worldwide, including Bellus Skin™ serum, a premium anti-wrinkle skin care product licensed from Korea (Madenco Biosciences Inc.). Quest is also developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications (AmrutBio).

Website home page pic

Link to Quest PharmaTech Inc. Fact Sheet

Press releases 2016

August 5, 2016
Quest PharmaTech Inc. (TSX-V: QPT) (“Quest”or the “Company”), today announces the filing on SEDARof restated financial statements for the year ended January 31, 2016

Mar 22, 2016
Quest PharmaTech’s Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

Press releases 2015

Dec 10, 2015
Quest PharmaTech Receives U.S. $2 Million for its ImmunoPhotodynamic Therapy Assets

Dec 1, 2015
Quest PharmaTech Announces Results from its 2015 AGM